Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (17232)	6/30/1999 11:12:00 AM
From: onza	Respond to of 25711

APPI news: Wednesday June 30, 10:30 am Eastern Time Company Press Release SOURCE: Advanced Plant Pharmaceuticals, Inc. Advanced Plant Pharmaceuticals Inc. - APPI - Signs Exclusive Distribution Agreement with Ambar Pharmacies and Health NEW YORK, June 30 /PRNewswire/ -- Advanced Plant Pharmaceuticals, Inc. (OTC Bulletin Board: APPI - news) a company that utilizes whole plants to develop all natural dietary supplements, signed an exclusive Distribution Agreement with Ambar Pharmacies and Health, Inc. in which Ambar agrees to distribute stated minimums of APPI's products in Israel. The exclusive agreement, APPI's first firm commitment from an overseas corporation, requires Ambar to purchase certain minimum quantities of APPI's dietary supplements, ''ACA'' and ''Lo-Chol.'' Ambar, which was established by Ambar Abraham a licensed pharmacist, and Dr. Reuven Barak M.D., distributes Chinese medicines and all natural products to pharmacies, hospitals, clinics, shops, and practitioners all over Israel. Ambar has the largest updated mailing list of practitioners with patients, most of which are working with Ambar. ''Your company holds a product, that the Israeli market requires,'' said Ambar Abraham, General Manager for Ambar. ''With our expertise, we will take responsibility for the marketing of your products.'' Mr. Abraham further stated, ''the advantage of us representing APPI is that we will exclusively focus on your products, in terms of bringing the sales to their maximum money potential.'' APPI, which is currently negotiating similar overseas distribution agreements, hopes that this agreement with Ambar will be the first of many distribution agreements. APPI, after several years of research and development, began marketing its products in January of this year. The company hopes to announce further agreements in the near future. Company information, and ordering of product can be obtained on APPI's Internet web site located at advancedplantpharm.com APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has met FDA nutritional specifications for the marketing of its Cholesterol lowering agent ''Lo-Chol'' in the USA, and has received the first IND from the FDA for a whole plant pharmaceutical, Abavca/ACA, which has potential as an immunomodulater in the treatment of patients infected with HIV, the virus that causes AIDS. APPI's Whole Plant Pharmaceutical Grade Process is trade secret and patent pending. Utilization of the APPI process converts a whole plant into the best standardized pharmaceutical grade product. This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. CONTACT: Barry Clare of Advanced Plant Pharmaceuticals Inc., 212-402-7878; or Ambar Abraham of Ambar Pharmacies & Health, +972-3-75235543. SOURCE: Advanced Plant Pharmaceuticals, Inc.